BioSpace News Archive

Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based in China , will use Olink® Explore 3072 to analyze the samples to serve a new large scale cohort study in China.

2021 Fourth-Quarter Sales of $24.8 Billion reflecting growth of 10.4%, operational sales growth of 11.6% and adjusted operational sales growth of 12.3%.

Imara Inc. today announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for tovinontrine (IMR-687).

ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will participate in the B. Riley Securities Oncology Conference.

Sierra Oncology, Inc. today announced it has entered into a term loan agreement with Oxford Finance, LLC that is designed to primarily support the commercial preparation and potential launch of momelotinib, an investigational agent for the treatment of myelofibrosis, a rare form of blood cancer.

SIGA Technologies, Inc. today announced that it entered into a collaboration with Bioarchitech, a United Kingdom-based biotech company developing immunotherapy for the treatment of cancer.

Summit Therapeutics Inc. today announced that the Company’s Board of Directors has approved a rights offering available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of the market on February 4, 2022 (the “Record Date”).

CinDome Pharma, Inc. (“CinDome”), a clinical-stage biopharmaceutical company and member of the CinRx Pharma portfolio, today announced the negative results of a clinical thorough QT/QTc study of CIN-102 (deudomperidone) in healthy individuals.

Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in the United States.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for CB 4332 for the treatment of Complement Factor I (CFI) deficiency (CFID).